|1.||Marshall, Anikò: 1 article (06/2014)|
|2.||Bale, Tracy L: 1 article (06/2014)|
|3.||Chen, Alon: 1 article (06/2014)|
|4.||Howerton, Alexis R: 1 article (06/2014)|
|5.||Fluharty, Jessica M: 1 article (06/2014)|
|6.||Daniels, Derek: 1 article (06/2014)|
|7.||Roland, Alison V: 1 article (06/2014)|
|8.||Beck, Sheryl G: 1 article (06/2014)|
|9.||Larson, Alice A: 1 article (09/2013)|
|10.||Nunez, Myra G: 1 article (09/2013)|
|1.||Mood Disorders (Mood Disorder)
06/01/2014 - "These studies demonstrate convincing sex differences in CRFr1 activity in the DR, where blunted female responses to NBI 35965 and CRF suggest unique stress modulation of the DR. These sex differences might underlie affective disorder vulnerability and differential sensitivity to pharmacologic treatments developed to target the CRF system, thereby contributing to a current lack of CRFr1 antagonist efficacy in clinical trials."
09/19/2003 - "Stress-induced visceral hyperalgesia was abolished by NBI 35965 (20 mg/kg, s.c.). "
09/19/2003 - "The data show that NBI 35965 is a novel water-soluble selective CRF1 antagonist with bioavailability to the brain upon peripheral administration and that CRF1 receptor signaling pathways are involved in water avoidance stress-induced hyperalgesia to colorectal distention and stimulation of colonic transit."
09/19/2003 - "A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats."
09/01/2013 - "Pretreatment with the CRF2 receptor antagonist astressin 2B, but not the CRF1 receptor antagonist NBI-35965, attenuated this hyperalgesia. "
|1.||CRF receptor type 1
|3.||CRF receptor type 2